OncoMatch/Clinical Trials/NCT06530550
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Is NCT06530550 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PI3K inhibitor for lymphoma, t-cell.
Treatment: PI3K inhibitor — Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Linperlisib or Duvelisib, with an expected overall response rate of 60% for PI3K inhibitor treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Prior therapy
Cannot have received: PI3K inhibitor
Subjects who have previously used any PI3K inhibitors
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 90 days before the first dose of study treatment
Received autologous hematopoietic stem cell transplantation within 90 days before the first dose of study treatment
Cannot have received: allogeneic bone marrow or hematopoietic stem cell transplantation
history of allogeneic bone marrow or hematopoietic stem cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify